Palatin Technologies, Inc. operates as a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics. The company's programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor (NPR) systems. Its primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). In addition, the company has drug candidates or development programs for obesity, erectile dysfunction (ED), cardiovascular diseases, pulmonary diseases, inflammatory diseases, and dermatologic diseases. Drug Development Programs Bremelanotide is a subcutaneous injectable peptide melanocortin receptor agonist for treatment of HSDD in premenopausal women. Bremelanotide, which is a melanocortin agonist, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone). Bremelanotide has completed the efficacy portion of patient studies in the primary Phase 3 clinical studies. Melanocortin receptor-4 compounds for treatment of obesity and diabetes. PL-3994 is a NPR-A, agonist for treatment of cardiovascular and pulmonary indications. PL-3994 is the company’s primary NPR product candidate, and is a synthetic mimetic of the neuropeptide hormone atrial natriuretic peptide (ANP). PL-3994 is in development for treatment of heart failure, acute exacerbations of asthma and refractory hypertension. Melanocortin receptor-1 is agonist peptides for treatment of inflammatory and dermatologic disease indications. Melanocortin Receptor-Specific Programs Bremelanotide for HSDD: The company is developing subcutaneously administered bremelanotide for the treatment of HSDD in premenopausal women. Bremelanotide is a melanocortin agonist with a mechanism of action involving activation of endogenous neuronal pathways regulating sexual arousal and desire responses. Melanocortin receptor-1 Peptide Agonists: The company has conducted preclinical animal studies with Melanocortin receptor-1 peptide drug candidates for inflammatory disease and autoimmune indications. The Melanocortin receptor-1 is upregulated in various diseases, including inflammatory bowel disease, nephritis, which is inflammation of the kidneys, and rheumatoid arthritis, and ocular indications, such as uveitis and dry eye. Melanocortin receptor-1 peptides also have potential application in various dermatologic indications, including vitiligo and erythropoietic protoporphyria. Melanocortin receptor-4 Peptide and Small Molecule Agonists: The company has developed a series of highly selective Melanocortin receptor-4 peptides and is developing orally active small molecules. In developing these compounds, the company examined effectiveness in animal models of sexual response, obesity, and related metabolic signals, and also determined cardiovascular effects, primarily looking at changes in blood pressure. Other Melanocortin Receptor-Specific Programs: The company is continuing drug discovery efforts in the melanocortin receptor field, primarily developing peptide compounds, including Melanocortin receptor-1 agonists and peptides specific for Melanocortin receptor-4, including both agonists and antagonists. NPR-Specific Programs: The NPR system has various cardiovascular functions, and therapeutic agents modulating this system might be useful in treatment of heart failure, acute asthma, other pulmonary diseases and hypertension. The company has designed and is developing candidate drugs that are selective for different NPRs, including NPR-A, NPR-B,NPRC, and both NPR-A and NPR-B. PL-3994: PL-3994 is the company’s primary NPR product candidate, and is a synthetic mimetic of the neuropeptide hormone ANP and an NPR-A agonist. PL-3994 is in development for treatment of heart failure, acute exacerbations of asthma and refractory hypertension. PL-3994 activates NPR-A, a receptor known to play a role in cardiovascular homeostasis. Strategy The key elements of the company’s business strategy include using its technology and expertise to develop and commercialize products in its active drug development pr
palatin technologies inc (PTN:NYSE Amex)
Cedar Brook Corporate Center
4B Cedar Brook Drive
Cranbury, NJ 08512
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for PTN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PALATIN TECHNOLOGIES INC, please visit www.palatin.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.